Literature DB >> 17721196

Epstein-Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients.

Namsoo Suh1, Helen Liapis, Joseph Misdraji, Elizabeth M Brunt, Hanlin L Wang.   

Abstract

Epstein-Barr virus (EBV) hepatitis is an uncommon, almost always self-limited disease in immunocompetent patients. Accurate diagnosis is imperative for appropriate clinical management. The aim of this study was to compare 3 available methods for EBV detection on routinely processed liver biopsies to determine their effectiveness in aiding the diagnosis. In 6 of the 8 cases of EBV hepatitis, EBV was detected by both polymerase chain reaction (PCR) for EBV DNA and in situ hybridization (ISH) for EBV early RNA (EBER). EBV was detected by PCR only in 1 case, and by ISH only in another. EBER-positive cells detected by ISH were typically few and individually distributed in the portal tracts and sinusoids. Immunohistochemical staining for EBV latent membrane proteins was negative in all 8 cases. Five cases of chronic hepatitis C used as negative controls were negative by all 3 detection methods for EBV. These data indicate that PCR and ISH are equally sensitive in detecting EBV in routinely processed liver biopsies. The ready implementation of ISH in pathology laboratories makes it a useful ancillary tool in confirming the diagnosis of EBV hepatitis in equivocal cases. However, EBER-positive cells can be sparse and easily overlooked. Immunohistochemistry for EBV latent membrane proteins apparently has no utility in the diagnosis of EBV hepatitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721196     DOI: 10.1097/PAS.0b013e31802ffdd5

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

Review 1.  Drug-induced Liver Injury: The Hepatic Pathologist's Approach.

Authors:  David E Kleiner
Journal:  Gastroenterol Clin North Am       Date:  2017-06       Impact factor: 3.806

Review 2.  Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group.

Authors:  Jessica L Mellinger; Lorenzo Rossaro; Willscott E Naugler; Satish N Nadig; Henry Appelman; William M Lee; Robert J Fontana
Journal:  Dig Dis Sci       Date:  2014-01-25       Impact factor: 3.199

Review 3.  Infectious diseases and the liver.

Authors:  Rohit Talwani; Bruce L Gilliam; Charles Howell
Journal:  Clin Liver Dis       Date:  2011-02       Impact factor: 6.126

4.  Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data.

Authors:  Chad M Vanderbilt; Anita S Bowman; Sumit Middha; Kseniya Petrova-Drus; Yi-Wei Tang; Xin Chen; Youxiang Wang; Jason Chang; Natasha Rekhtman; Klaus J Busam; Sounak Gupta; Meera Hameed; Maria E Arcila; Marc Ladanyi; Michael F Berger; Snjezana Dogan; Ahmet Zehir
Journal:  J Mol Diagn       Date:  2022-03-22       Impact factor: 5.341

5.  Detection of Epstein Barr virus by chromogenic in situ hybridization in cases of extra-hepatic biliary atresia.

Authors:  Fatemeh Mahjoub; Reza Shahsiah; Farid Azmoudeh Ardalan; Guiti Iravanloo; Mehri Najafi Sani; Abdolmajid Zarei; Maryam Monajemzadeh; Fatemeh Farahmand; Setareh Mamishi
Journal:  Diagn Pathol       Date:  2008-04-28       Impact factor: 2.644

6.  Macular Amyloidosis and Epstein-Barr Virus.

Authors:  Yalda Nahidi; Naser Tayyebi Meibodi; Zahra Meshkat; Narges Nazeri
Journal:  Dermatol Res Pract       Date:  2016-02-14

Review 7.  Viral Hepatitis Other than A, B, and C: Evaluation and Management.

Authors:  Amanda Cheung; Paul Kwo
Journal:  Clin Liver Dis       Date:  2020-04-13       Impact factor: 6.126

8.  Syphilis Reactivates Latent Epstein-Barr Virus Reservoir via Toll-Like Receptor 2 and B-Cell Receptor Activation.

Authors:  Julia R Hirsiger; Philipp S Fuchs; Peter Häusermann; Bojana Müller-Durovic; Thomas Daikeler; Mike Recher; Hans H Hirsch; Luigi Terracciano; Christoph T Berger
Journal:  Open Forum Infect Dis       Date:  2019-07-03       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.